Press Releases

2025

WuXi Biologics Showcase Green CRDMO at 2025 JPM, Which Achieves up to 80% PCF Reduction

Business

Feb. 06, 2025

WuXi Biologics Showcase Green CRDMO at 2025 JPM, Which Achieves up to 80% PCF Reduction

On January 15th, Dr. Chris Chen, CEO of WuXi Biologics, introduced the company’s innovative green biologics solution – Green CRDMO – at the 2025 J.P. Morgan Healthcare Conference held in San Francisco, California. By integrating ESG concepts and green technologies into the entire value chain of biologics research, development, and manufacturing, and fully utilizing lean management systems, WuXi Biologics Green CRDMO solutions can achieve a product carbon footprint (PCF) reduction of up to 80%.

In his comments, Dr. Chen said, “As a leading global CRDMO, WuXi Biologics regards sustainability as the cornerstone of our business growth strategy, aligning it with our corporate vision and mission to deliver strong ESG performance. Furthermore, the company is continually driving green technology innovation to provide advanced end-to-end Green CRDMO solutions for our partners worldwide.”

The company’s Green CRDMO case – titled “Leading in Green Biologics Solutions for a Healthier Future” – was selected in November 2024 by the United Nations Global Compact (UNGC) as one of the best 20 case examples of sustainable development over the past 20 years. It was the only pharmaceutical case recognized by the UNGC.

Leading in Green Biologics Solutions for a Healthier Future

Click on the link for the full report：https://cn.unglobalcompact.org/Management.html

Green Research

WuXi Biologics provides advanced and comprehensive services in biologics research for the discovery, identification, and screening of monoclonal antibodies, bispecific antibodies, and multispecific antibodies. With multiple innovative technology platforms, the company empowers its global partners to develop innovative antibodies.

WuXiBody™, WuXi Biologics’ universal and proprietary bispecific antibody technology platform, has strong compatibility, and – through exquisite protein design – can combine almost any ordinary monoclonal antibody sequence. Its unique structure can flexibly construct various formats with different valencies (e.g., 2, 3 or 4 binding sites), and its excellent developability solves CMC challenges – accelerating the research and development process by 6-18 months, and significantly reducing production costs. In addition, WuXiBody™ contributes significantly to sustainable development as it minimizes impact on the environment by reducing the need for natural resources, electricity and other energy consumption.

In January 2023, WuXi Biologics leveraged WuXiBody™, along with the company’s CD3 antibody technology platform, to enter a license agreement with GSK for multiple novel bi-and multispecific T-cell engagers. In January 2025, the company announced an agreement with Candid Therapeutics for a trispecific T-cell engager, further evidencing the recognized capabilities of WuXiBody™ to deliver transformative and customized multispecific antibodies.

Green Development

For biologics development, WuXi Biologics’ service platforms include: a cell line development platform WuXia^TM; a comprehensive ADC drug development technology platform, WuXiDAR4^TM; a customized high-concentration DP development platform, WuXiHigh^TM; an ultra-high productivity continuous processing platform, WuXiUP ™; and an ultra-intensified fed-batch platform WuXiUI™, etc.

The WuXiUP™ platform can significantly decrease production costs while achieving 5-15 times increase in productivity compared to a traditional process. At the same time, it can lower resin use and reduce the demand for production building space, greatly lowering the facility carbon footprint. While ensuring the highest quality, the WuXiUI™ platform can achieve 3-6 times higher productivity compared to a traditional process. In addition, compared with the traditional fed-batch (TFB) production process, it can lessen environmental impacts by up to 60% throughout the entire lifecycle due to its realization of substantial reductions in media use and waste generation. More specifically, the environmental impacts assessed include climate change, ozone depletion, acidification, resource consumption, water resource consumption, particulate matter, etc.

In August 2024, Merck announced it would acquire full global rights to bispecific antibody CN201 from Curon Biopharmaceutical, one of the clients enabled by WuXi Biologics. CN201 is developed using four of WuXi Biologics’ proprietary technology platforms: WuXiBody™, WuXiUP™, TCE and WuXia^TM. The deal is a reflection of client recognition for WuXi Biologics’ leadership in technology innovation and perfect execution.

Green Manufacturing

Over the past six years, WuXi Biologics has established itself as a leader and pioneer in SUT manufacturing, building a strong SUT commercial manufacturing capability. By leveraging scale-out and continuous process innovation, SUT manufacturing has been applied in over 300 batches of production, spanning from 4000 to 16000 liters across multiple facilities. The SUT manufacturing can achieve comparable COGs as stainless-steel reactors, providing more eco-friendly solutions. Notably, The SUT offers clients greater flexibility and a wider range of options.

Compared with a traditional stainless steel production process, SUT can achieve up to 70% water resource savings, 33% resource consumption reduction, and approximately 70% in product carbon footprint reduction per gram of protein. Even more significantly, when compared with the combination of TFB and traditional stainless-steel process, the combination of WuXiUI™ and SUT can achieve up to 80% in product carbon footprint reduction per gram of protein, continuously breaking through towards green biologics manufacturing.

In December 2024, WuXi Biologics’ cutting-edge greenfield site in Ireland successfully completed multiple 16,000L PPQ runs, representing one of the largest cell culture processes in the world using SUT and setting a new benchmark for the entire biopharmaceutical industry. As a flagship site of Factory of the Future, the site proactively optimizes its energy consumption and has achieved a 100% renewable electricity supply. It consistently adheres to international standards in environmental protection, sustainable energy development, and employee health and safety, and has achieved outstanding results as one of the most eco-friendly sites within the company’s extensive global network.

Enabling the Industry for Green Transformation

As an active participant in the UNGC, WuXi Biologics is committed to driving innovation in green biologics technology, continuously improving operational efficiency, advancing Green CRDMO solutions for the whole industry, and making contributions to the United Nations Sustainable Development Goals. In recent years, WuXi Biologics’ ESG strategy and initiatives have made significant progress and gained widespread recognition. The company was granted an MSCI AAA Rating and included in the Dow Jones Sustainability Indices for two consecutive years; awarded the distinguished Platinum Medal by EcoVadis; recognized as an Industry and Regional ESG Top-Rated Company by Sustainalytics; named to the CDP Water Security “A list” and awarded an “A-” CDP Climate Change score; selected as a Constituent of the FTSE4Good Index Series; and listed in the Hang Seng ESG 50 Index.

WuXi Biologics promotes transparent, high ethical standards, and responsible practices in the global supply chain, and has been recognized with a “Sustainable Supply Chain Leadership Award.” As a supplier partner of the Pharmaceutical Supply Chain Initiative (PSCI), the company helps promote the construction of a responsible value chain, and collaborates with global supply chain partners to achieve outstanding performance in ethics, labor and human rights, health and safety, environmental issues, and management systems. It also actively supports public policies, such as the Paris Agreement, by collaborating with industry associations and global organizations to improve energy efficiency across the entire biopharmaceutical industry; takes on social responsibility in addressing climate change through the annual CDP environmental information disclosure; and continues its commitment to the Science Based Target Initiative (SBTi).

Going forward, WuXi Biologics will further explore the use of renewable energy, reduce its carbon emissions, improve water and waste management, and actively pursue ESG excellence. At the same time, it will continue to provide innovative end-to-end Green CRDMO solutions for clients worldwide, and work together with all partners to drive the entire value chain towards a greener and healthier future.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects).

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to be an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

Contacts

ESG

esg@wuxibiologics.com

Media

PR@wuxibiologics.com

List